LENZ Therapeutics Names Daniel Chevallard Interim CEO
Evert Schimmelpennink will leave his President and CEO roles and the board on December 1, 2026, when CFO Daniel Chevallard will become interim President and CEO.
Related stories
Nasdaq pauses volatility trading
Nasdaq announced a volatility trading pause at 11:22 a.m.
L impact | EQUITY | Oct 29, 2026, 03:27 PM UTC
Caterpillar quarterly profit beats expectations; full-year sales outlook unchanged
Caterpillar reported quarterly profit above expectations and kept its full-year sales outlook unchanged.
M impact | EQUITY | Oct 29, 2026, 03:25 PM UTC
Maxland Director Dennis Lim Acquires 100,000 Ordinary Rights
M impact | EQUITY | Oct 29, 2026, 03:25 PM UTC
Energa Milestone Removes Contract Termination Risk and Ends Monthly Penalties
Energa says a milestone achievement removes the risk of capacity market contract termination and ends monthly penalties of 1.1 million zlotys.
M impact | EQUITY | Oct 29, 2026, 03:24 PM UTC
Federal Home Loan Bank of Dallas Reports Third-Quarter 2026 Results
The bank reported third-quarter 2026 operating results.
M impact | EQUITY | Oct 29, 2026, 03:24 PM UTC
Adidas CEO Sees Possible Upside to Full-Year Revenue Guidance
Adidas CEO says there might be upside to the company's full-year revenue guidance.
M impact | EQUITY | Oct 29, 2026, 03:23 PM UTC